Evidence map›Paper›PMID 29698409›Full record

ArticlePloS one2018

Heparin free dialysis in critically sick children using sustained low efficiency dialysis (SLEDD-f): A new hybrid therapy for dialysis in developing world.

Sidharth Kumar Sethi, Shyam B Bansal, Anshika Khare, Maninder Dhaliwal, Veena Raghunathan, Nikita Wadhwani, Ashish Nandwani, Dinesh Kumar Yadav, Amit Kumar Mahapatra, Rupesh Raina

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Kidney Support Therapy: Recent Advances.Indian journal of pediatrics · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Pediatric acute kidney injury: new advances in the last decade.Kidney research and clinical practice · 2021
    Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Sidharth Kumar SethiKidney Institute, Medanta, The Medicity, Gurgaon, Haryana, India.ORCID 0000-0002-1516-3393
Shyam B BansalKidney Institute, Medanta, The Medicity, Gurgaon, Haryana, India.
Anshika KhareNortheast Ohio Medical University, Rootstown, Ohio, United States of America.
Maninder DhaliwalPediatric Critical Care, Medanta, The Medicity, Gurgaon, Haryana, India.
Veena RaghunathanPediatric Critical Care, Medanta, The Medicity, Gurgaon, Haryana, India.
Nikita WadhwaniKidney Institute, Medanta, The Medicity, Gurgaon, Haryana, India.
Ashish NandwaniKidney Institute, Medanta, The Medicity, Gurgaon, Haryana, India.
Dinesh Kumar YadavKidney Institute, Medanta, The Medicity, Gurgaon, Haryana, India.
Amit Kumar MahapatraKidney Institute, Medanta, The Medicity, Gurgaon, Haryana, India.
Rupesh RainaPediatric Nephrology, Akron Children's Hospital, Akron, Ohio, United States of America.
Medanta The Medicity · INAkron Children's Hospital · USNortheast Ohio Medical University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn critically sick adults, sustained low efficiency dialysis [SLED] appears to be better tolerated hemodynamically and outcomes seem to be comparable to CRRT. However, there is paucity of data in critically sick children. In children, two recent studies from Taiwan (n = 11) and India (n = 68) showed benefits of SLED in critically sick children. AIMS AND

objectivesThe objective of the study was to look at the feasibility and tolerability of sustained low efficiency daily dialysis-filtration [SLEDD-f] in critically sick pediatric patients. MATERIAL AND

methodsDesign: Retrospective study Inclusion criteria: All pediatric patients who had undergone heparin free SLEDD-f from January 2012 to October 2017. Measurements: Data collected included demographic details, vital signs, PRISM III at admission, ventilator parameters (where applicable), number of inotropes, blood gas and electrolytes before, during, and on conclusion of SLED therapy. Technical information was gathered regarding SLEDD-f prescription and complications.

resultsBetween 2012-2017, a total of 242 sessions of SLEDD-f were performed on 70 patients, out of which 40 children survived. The median age of patients in years was 12 (range 0.8-17 years), and the median weight was 39 kg (range 8.5-66 kg). The mean PRISM score at admission was 8.77±7.22. SLEDD-f sessions were well tolerated, with marked improvement in fluid status and acidosis. Premature terminations had to be done in 23 (9.5%) of the sessions. There were 21 sessions (8.6%) terminated due to hypotension and 2 sessions (0.8%) terminated due to circuit clotting. Post- SLEDD-f hypocalcemia occurred in 15 sessions (6.2%), post- SLEDD-f hypophosphatemia occurred in 1 session (0.4%), and post- SLEDD-f hypokalemia occurred in 17 sessions (7.0%).

conclusionsThis study is the largest compiled data on pediatric SLEDD-f use in critically ill patients. Our study confirms the feasibility of heparin free SLEDD-f in a larger pediatric population, and even in children weighing <20 kg on inotropic support.

Indexed as

Critical CareAcute Kidney InjuryAdolescentChildChild, PreschoolCritical IllnessDeveloping CountriesFeasibility StudiesFollow-Up StudiesHumansInfantLength of StayRenal DialysisRetrospective StudiesTreatment Outcome

Identifiers

PMID29698409
PMCPMC5919674
OpenAlexW2800153422

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.